Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

4617 - A Phase 3 study of first-line durvalumab vs platinum-based chemotherapy in patients with advanced NSCLC and high PD-L1 expression: PEARL

Date

09 Sep 2017

Session

Poster display session

Presenters

Yi-Long Wu

Citation

Annals of Oncology (2017) 28 (suppl_5): v460-v496. 10.1093/annonc/mdx380

Authors

Y. Wu1, S. Lu2, S. Clarke3, K. Lactionov4, P. Li5, M. Kirkby5, Y. Xie6, P. Stockman7

Author affiliations

  • 1 Guangdong Lung Cancer Institute, Guangdong General Hospital, 510080 - Guangzhou/CN
  • 2 Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai/CN
  • 3 Northern Sydney Cancer Centre, Royal North Shore Hospital, 2065 - St Leonards/AU
  • 4 Medical Oncology, N. N. Blokhin Russian Cancer Research Center, Moscow/RU
  • 5 Medical Oncology, AstraZeneca, Beijing/CN
  • 6 Cdu (china Development Unit) B&i, AstraZeneca, Shanghai/CN
  • 7 Global Medicines Development, AstraZeneca, Alderley Park/GB
More

Resources

Abstract 4617

Background

NSCLC is highly prevalent in Asia. Differences in outcomes to therapy, including longer survival and higher response rates, have been noted in Asian vs Caucasian NSCLC patients due to the higher prevalence of targetable oncogenes (i.e. EGFR sensitizing mutation or ALK translocation) in the Asian population. Until recently, standard of care (SoC) first-line treatment of EGFR/ALK wild-type advanced NSCLC comprised systemic platinum-based doublets. However, over recent years, immune checkpoint blockade has also become an important option, including in the first-line setting where pembrolizumab is approved in the US, EU and Japan in patients whose tumours express high levels of PD-L1. Durvalumab is a selective, high-affinity, anti-PD-L1 antibody that has shown antitumour activity and manageable tolerability across multiple tumour types, including NSCLC. The PEARL study aims to assess first-line durvalumab vs SoC in predominantly Asian populations with EGFR/ALK wild-type advanced NSCLC and high tumour PD-L1 expression.

Trial design

PEARL (NCT03003962) is a randomised, open-label, multicentre Phase 3 study. Eligible patients are immunotherapy- and chemotherapy-naïve with Stage IV, EGFR/ALK wild-type NSCLC, high PD-L1 expression (≥25% tumour cells with membrane staining using the Ventana PD-L1 [SP263] Assay) and ECOG performance status of 0 or 1. ∼440 patients will be stratified by level of PD-L1 expression, histology and smoking status, and randomised 1:1 to receive either durvalumab (20 mg/kg i.v. every 4 weeks [q4w]) or SoC platinum-based chemotherapy until disease progression. The co-primary endpoints are PFS using blinded independent central review assessments according to RECIST v1.1 and OS. Secondary endpoints include ORR; duration of response; proportion of patients alive and progression free at 12 months; PFS after subsequent anticancer therapy; disease-related symptoms and HRQoL; immunogenicity; safety (CTCAE v4.03) and tolerability. Tumour assessments will be performed q6w for the first 48 weeks and then q8w as defined by RECIST v1.1 until confirmed disease progression. Recruitment is ongoing in Australia, China, Republic of Korea, Russia, Thailand and Vietnam.

Clinical trial identification

NCT03003962 (release date: December 15, 2016)

Legal entity responsible for the study

AstraZeneca PLC

Funding

AstraZeneca

Disclosure

Y-L. Wu: Speaker fees: Roche, AstraZeneca, Eli Lilly, Sanofi, Pfizer. S. Lu: Speakers\' Bureau: AstraZeneca, Eli Lilly, Roche, Sanofi Corporate sponsored research: AstraZeneca, Boehringer-Ingelheim, Hutchison, Roche Consultant: AstraZeneca, Boehringer-Ingelheim, Hutchison, MediPharma, Roche. S. Clarke: Corporate sponsored research: Ipsen, Merck Honoraria: AstraZeneca, Ipsen, Merck. K. Lactionov: Consultant BMS, AstraZeneca, MSD, Pfizer and travel grants BMS, AstraZeneca, MSD, Pfizer P. Li, M. Kirkby, P. Stockman: AstraZeneca: full-time employment and stock ownership. Y. Xie: AstraZeneca: full-time employment.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.